Nykode Therapeutics AS Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 20, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	104	85	623	787	2,333	2,037
Market Cap Growth	46.19%	-86.44%	-20.78%	-66.26%	14.52%	-
Enterprise Value	49	-23	478	574	2,168	2,021
Last Close Price	0.29	0.12	1.00	1.65	4.32	-
PE Ratio	-	-	-	-	-	16.64
PS Ratio	16.58	9.56	51.73	93.16	74.18	11.55
PB Ratio	1.23	0.64	4.02	5.36	13.67	13.93
P/TBV Ratio	1.23	0.64	4.03	5.36	13.67	13.93
P/FCF Ratio	-	-	-	-	9341.31	13.83
P/OCF Ratio	-	-	-	-	2296.91	13.82
EV/Sales Ratio	7.57	-	39.62	67.90	68.94	11.46
EV/EBITDA Ratio	-	-	-	-	-	13.87
EV/EBIT Ratio	-	-	-	-	-	13.87
EV/FCF Ratio	-1.62	-	-	-	8682.61	13.73
Debt / Equity Ratio	0.03	0.03	0.03	0.04	0.04	0.00
Debt / EBITDA Ratio	-	-	-	-	-	0.00
Debt / FCF Ratio	-	-	-	-	25.25	0.00
Net Debt / Equity Ratio	-0.61	-0.82	-0.92	-1.28	-1.14	-1.17
Net Debt / EBITDA Ratio	2.37	2.35	2.73	3.81	20.70	-1.17
Net Debt / FCF Ratio	1.71	2.18	1.59	8.60	-778.98	-1.16
Asset Turnover	0.05	0.05	0.06	0.04	0.14	1.64
Quick Ratio	17.14	12.78	7.94	5.41	8.12	17.36
Current Ratio	17.14	12.87	8.04	5.44	8.16	17.38
Return on Equity (ROE)	-9.10%	-25.25%	-21.42%	-24.35%	-5.05%	145.07%
Return on Assets (ROA)	-12.08%	-16.70%	-16.90%	-13.64%	-2.72%	84.59%
Return on Invested Capital (ROIC)	-71.49%	-250.18%	-	-	-	-
Return on Capital Employed (ROCE)	-26.00%	-33.50%	-31.00%	-29.10%	-4.60%	82.20%
Earnings Yield	-9.03%	-44.34%	-5.10%	-5.08%	-0.36%	6.01%
FCF Yield	-29.37%	-58.58%	-14.30%	-2.78%	0.01%	7.23%
Dividend Yield	-	70.64%	-	-	-	-
Buyback Yield / Dilution	22.32%	-8.66%	-3.58%	-1.32%	3.31%	-1.14%
Total Shareholder Return	22.32%	61.98%	-3.58%	-1.32%	3.31%	-1.14%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.